# US 2019/0153620 A1 · Libraries of diverse macrocyclic compounds and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153620 A1
- Document ID: US20190153620A1
- Status: Published application
- Kind: A1
- Application number: 16/302,043
- Filed: 2017-05-16
- Published: 2019-05-23
- Earliest claimed: 2016-05-16
- Assignees: Cyclenium Pharma Inc.
- Applicants: Cyclenium Pharma Inc.
- Inventors: Dwight MACDONALD; Daniel DUBÉ; Amal WAHHAB; Helmut THOMAS; Luc RICHARD; Mark L. PETERSON
- Web page: https://patentgrep.com/patent/US20190153620A1

## CPC

- C40B 30/06: by measuring effects on living organisms, tissues or cells
- C07D 255/02: not condensed with other rings
- C07D 257/02: not condensed with other rings
- C07D 259/00: Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/14: containing three or more hetero rings
- C40B 30/08: by measuring catalytic activity
- C40B 40/04: Libraries containing only organic compounds
- C40B 50/00: Methods of creating libraries, e.g. combinatorial synthesis
- C40B 50/14: Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure relates to novel macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

## Claims

### Claim 1

A library comprising at least two macrocyclic compounds chosen from compounds of formula (I) and salts thereof:
wherein:
X1 is selected from the group consisting of N, O and NR22, where R22 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl, when X1 is NR22, X1 can also form an optionally substituted four, five, six or seven-membered ring together with R2 and R5, if present in A, and, when X1 is N, X1 forms an optionally substituted four, five, six or seven-membered ring together with A;
X2 is selected from the group consisting of O and NR23, where R23 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, when X2 is not bonded to a carbonyl group in A or B, X2 can also be selected from S(O)q1 where q1 is 0-2, and R23 can also be selected from the group consisting of formyl, acyl, amino acyl, amido, amidino, carboxyalkyl, carboxyaryl and sulfonamide, and when X2 is NR23, X2 can also form an optionally substituted four, five, six or seven-membered ring together with R10, if present in A, or R12a, if present in B;
X3 is selected from the group consisting of N, O and NR24, where R24 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl, when X3 is NR24, X3 can also form an optionally substituted four, five, six or seven-membered ring together with R12b, if present in B, or R15, if present in D, and, when X3 is N, X3 forms an optionally substituted four, five, six or seven-membered ring together with D;
X4 is selected from the group consisting of O and NR25, where R25 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl, when X4 is not bonded to a carbonyl group in D, X4 can also be selected from S(O)q2 where q2 is 0-2, and R25 can also be selected from the group consisting of formyl, acyl, amino acyl, amido, amidino, carboxyalkyl, carboxyaryl and sulfonamide, and when X4 is NR25, X4 can also form an optionally substituted four, five, six or seven-membered ring together with R1 or R20, if present in D;
A, when X1 is O or NR22, is selected from the group consisting of:
(X1)—(CH2)n1a—(X2), (X1)—(CH2)n1b—X5—(CH2)n1c—(X2),
A, when X1 is N, is selected from the group consisting of:
where n1a is 2-10; n2, n3 and n4 are independently 0-4; n5 is 0-3; n1b and n1c are independently 1-4; n6a, n6b, n6c, n7a, n7b and n7c are independently 2-4, when X8a, X8b, X8c, X9a, X9b or X9c are CH2, n6a, n6b, n6c, n7a, n7b and n7c, respectively, can also be 0-1;
X5 is selected from the group consisting of O, CH═CH, S(O)q3 and NR26, where q3 is 0-2 and R26 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl;
X6 and X7 are independently selected from the group consisting of O and NR27, where R18 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl, when X6 or X7 are NR27, X6 and X7 can also form an optionally substituted four, five, six or seven-membered ring together with, respectively, R6 and R9;
X8a, X8b, X8c, X9a, X9b and X9c are independently selected from the group consisting of CH2, O and NR28, where R28 is selected from the group consisting of hydrogen, C1-C4 alkyl, formyl, acyl and sulfonyl;
Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, Z10, Z11 and Z12 are independently selected from the group consisting of N, N+—O− and CR29, where R29 is selected from the group consisting of hydrogen, hydroxy, alkoxy, amino, amido, amidino, guanidino, halogen, cyano, nitro, carboxy, carboxyalkyl, carboxyaryl, trifluoromethyl, C1-C6 alkyl, C3-C7 cycloalkyl, C2-C10 heterocycle, C6-C12 aryl, and C4-C10 heteroaryl, wherein in the group of Z1, Z2, Z3 and Z4, three or less within that group are N; wherein in the group of Z5, Z6, Z7 and Z8, three or less within that group are N; and wherein in the group of Z9, Z10, Z11 and Z12, three or less within that group are N; and
(X1) and (X2) indicate the site of bonding to X1 and X2 of formula (I), respectively;
B is selected from the group consisting of:
where (X2) and (X3) indicate the site of bonding to X2 and X3 of formula (I), respectively,
wherein, when A is
B is
D, when X3 is O or NR24, is selected from the group consisting of:
(X3)—(CH2)n8—(X4), (X3)—(CH2)n9a—X10—(CH2)n9b—(X4),
D, when X3 is N, is selected from the group consisting of:
where n8 is 2-10; n9a and n9b are independently 2-4; n10, n11 and n12 are independently 0-4; n13 is 0-3; n14a, n14b and n14c are independently 0-4; n15a, n15b, n15c, n16a, n16b, n16c, n17a, n17b, n17c, n18a, n18b, n18c, n19a, n19b and n19c are independently 2-4, when X13a, X13b, X13c, X15a, X15b, X15c, X16a, X16b, X16c, X18a, X18b or X18c are CH2, n15a, n15b, n15c, n17a, n17b, n17c, n18a, n18b, n18c, n19a, n19b and n19c, respectively, can also be 0-1;
X10 is selected from the group consisting of O, CH═CH, S(O)q4 and NR30, where q4 is 0-2 and R30 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl;
X11 and X12 are independently selected from the group consisting of O and NR31, where R31 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl, when X11 or X12 are NR28, X11 and X12 can also form an optionally substituted four, five, six or seven-membered ring together with, respectively, R16 and R19;
X13a, X13b, X13c, X15a, X15b, X15c, X16a, X16b, X16c, X18a, X18b and X18c are independently selected from the group consisting of CH2, O and NR32, where R32 is selected from the group consisting of hydrogen, C1-C4 alkyl, formyl, acyl and sulfonyl;
X14a, X14b and X14c are independently selected from the group consisting of O and NR33, where R33 is selected from the group consisting of hydrogen, C1-C4 alkyl, formyl, acyl and sulfonyl;
X17a, X17b and X17c are independently selected from the group consisting of O, S(O)q5 NR34 and CR35R36, where q5 is 0-2, R34 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C015 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl;
R35 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl; and R36 is selected from the group consisting of hydrogen and C1-C6 alkyl; or R35 and R36 together with the carbon to which they are bonded form an optionally substituted three, four, five, six or seven-membered ring;
Z13, Z14, Z15, Z16, Z17, Z18, Z19, Z20, Z21, Z22, Z23, Z24, Z25, Z26, Z27, Z28, Z29, Z30, Z31, Z32, Z33, Z34, Z35 and Z36 are independently selected from the group consisting of N, N+—O− and CR37, where R37 is selected from the group consisting of hydrogen, hydroxy, alkoxy, amino, amido, amidino, guanidino, halogen, cyano, nitro, carboxy, carboxyalkyl, carboxyaryl, trifluoromethyl, C1-C6 alkyl, C3-C7 cycloalkyl, C2-C10 heterocycle, C6-C12 aryl, C4-C10 heteroaryl, wherein in the group of Z13, Z14, Z15 and Z16, three or less within that group are N; wherein in the group of Z17, Z18, Z19 and Z20, three or less within that group are N; wherein in the group of Z21, Z22, Z23 and Z24, three or less within that group are N; wherein in the group of Z25, Z26, Z27 and Z28, three or less within that group are N; wherein in the group of Z29, Z30, Z31 and Z32, three or less within that group are N; and wherein in the group of Z33, Z34, Z35 and Z36, three or less within that group are N; and
(X3) and (X4) indicate the site of bonding to X3 and X4 of formula (I), respectively;
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12a, R12b, R13, R14, R15, R16, R17, R18, R19, and R20 are independently selected from the group consisting of:
where (#) indicates the site of bonding of the moiety to the remainder of the structure; p1, p2, p3, p4 and p5 are independently 0-5; p6 and p7 are independently 0-6;
W1 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, amido, carboxyalkyl, carboxyaryl, amidino, sulfonyl, sulfonamido and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
W2 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, acyl, amino acyl and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
W3 and W8 are independently selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
W4 is selected from the group consisting of hydrogen, halogen, trifluoromethyl, hydroxy and methyl;
W5 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
W6 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, acyl, carboxyalkyl, carboxyaryl, amido and sulfonyl; and
W7 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
wherein R1, when X4 is NR25, can also form an optionally substituted four, five, six or seven-membered ring together with NR25,
wherein R2, when X1 is NR22, can also form an optionally substituted four, five, six or seven-membered ring together with NR22;
wherein R5, when X1 is NR22, can also form an optionally substituted four, five, six or seven-membered ring together with NR22;
wherein R10, when X2 is NR23, can also form an optionally substituted four, five, six or seven-membered ring together with NR23;
wherein R12a, when X2 is NR23, can also form an optionally substituted four, five, six or seven-membered ring together with NR23;
wherein R12b, when X3 is NR24, can also form an optionally substituted four, five, six or seven-membered ring together with NR24;
wherein R15, when X3 is NR24, can also form an optionally substituted four, five, six or seven-membered ring together with NR24;
wherein R20, when X4 is NR25, can also form an optionally substituted four, five, six or seven-membered ring together with NR25; and
R11a, R11b, R21a and R21b are independently selected from the group consisting of hydrogen, fluorine, C1-C10 alkyl, C6-C12 aryl, hydroxy, alkoxy, aryloxy and amino.

### Claim 2 (depends on 1)

The library according to claim 1 wherein A is selected from the group consisting of:
where (X1) and (X2) indicate the site of bonding to X1 and X2 of formula (I), respectively.

### Claim 3 (depends on 1)

The library according to claim 1 wherein A is selected from the group consisting of:
wherein n2 is 0; n3 is 0-2; X6 is selected from the group consisting of NH and NCH3; R4 and R7 are hydrogen; R3, R5 and R6 are independently selected from the group consisting of:
where (#) indicates the site of bonding of the moiety to the remainder of the structure; and (X1) and (X2) indicate the site of bonding to X1 and X2 of formula (I), respectively.

### Claim 4 (depends on 1)

The library according to claim 1 wherein X1 is N and A is selected from the group consisting of:
where (X1) and (X2) indicate the site of bonding to X1 and X2 of formula (I), respectively.

### Claim 5 (depends on 1)

The library according to claim 1 wherein D is selected from the group consisting of:
where (X3) and (X4) indicate the site of bonding to X3 and X4 of formula (I), respectively.

### Claim 6 (depends on 1)

The library according to claim 1 wherein D is selected from the group consisting of:
wherein n10 is 0; n11 is 0-2; X11 is selected from the group consisting of NH and NCH3; R14 and R17 are hydrogen; R13, R15 and R16 are independently selected from the group consisting of:
where (#) indicates the site of bonding of the moiety to the remainder of the structure; and (X3) and (X4) indicate the site of bonding to X3 and X4 of formula (I), respectively.

### Claim 7 (depends on 1)

The library according to claim 1 wherein X3 is N and D is selected from the group consisting of:
where (X3) and (X4) indicate the site of bonding to X3 and X4 Of formula (I), respectively.

### Claim at position 8

8-16. (canceled)

### Claim 17 (depends on 1)

The library according to claim 1 comprising macrocyclic compounds selected from those with structures 1401-3813.

### Claim 18 (depends on 1)

The library according to claim 1 comprising macrocyclic compounds selected from those with structures 3816-3975.

### Claim at position 11

19-25. (canceled)

### Claim 26 (depends on 1)

The library according to claim 1 arrayed in at least one multiple sample holder.

### Claim at position 13

27-33. (canceled)

### Claim 34 (depends on 1)

A macrocyclic compound represented by formula (I) as described in claim 1, or salts thereof.

### Claim 35 (depends on 34)

The macrocyclic compound of claim 34 selected from the group consisting of structures 1401-3813 and pharmaceutically acceptable salts thereof.

### Claim 36 (depends on 34)

The macrocyclic compound of claim 34 selected from the group consisting of structures 3816-3975 and pharmaceutically acceptable salts thereof.

### Claim at position 17

37-48. (canceled)

### Claim 49 (depends on 1)

A method of using the library according to claim 1, said method comprising contacting said compounds of said library with a biological target so as to obtain the identification of compound(s) that modulate(s) the biological target.

### Claim at position 19

50-58. (canceled)

### Claim 59

A library comprising at least two macrocyclic compounds chosen from compounds of formula (II) and salts thereof:
wherein:
X21 is selected from the group consisting of N, O and NR49, where R49 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl, when X21 is NR49, X21 can also form an optionally substituted four, five, six or seven-membered ring together with R42, if present in G, and, when X21 is N, X21 forms an optionally substituted four, five, six or seven-membered ring together with G;
X22 is selected from the group consisting of O and NR50, where R50 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, when X22 is not bonded to a carbonyl group in G, X22 can also be selected from S(O)q21 where q21 is 0-2, and R50 can also be selected from the group consisting of formyl, acyl, amino acyl, amido, amidino, carboxyalkyl, carboxyaryl and sulfonamide;
X23 is selected from the group consisting of O and NR51, where R51 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl, when X23 is not bonded to a carbonyl group in K, X23 can also be selected from S(O)q22 where q22 is 0-2, and R51 can also be selected from the group consisting of formyl, acyl, amino acyl, amido, amidino, carboxyalkyl, carboxyaryl and sulfonamide, and when X23 is NR51, X23 can also form an optionally substituted four, five, six or seven-membered ring together with R41;
A, when X21 is O or NR49, is selected from the group consisting of:
(X21)—(CH2)n21a—(X22), (X21)—(CH2)n21b—X24—(CH2)n21c—(X22),
A, when X21 is N, is selected from the group consisting of:
where n21a is 2-10; n22 and n23 are independently 0-3; n21b and n21c are independently 1-4; n24a, n24b, n24c, n25a, n25b and n25c are independently 2-4, when X25a, X25b, X25c, X26a, X26b or X26c are CH2, n24a, n24b, n24c, n25a, n25b and n25c, respectively, can also be 0-1;
X24 is selected from the group consisting of O, CH═CH, S(O)q23 and NR52, where q23 is 0-2 and R52 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl;
X25a, X25b, X25c, X26a, X26b and X26c are independently selected from the group consisting of CH2, O and NR53, where R53 is selected from the group consisting of hydrogen, C1-C4 alkyl, formyl, acyl and sulfonyl;
Z41, Z42, Z42, Z44, Z45, Z46, Z47, Z48, Z49, Z50, Z51 and Z52 are independently selected from the group consisting of N, N+—O− and CR54, where R54 is selected from the group consisting of hydrogen, hydroxy, alkoxy, amino, amido, amidino, guanidino, halogen, cyano, nitro, carboxy, carboxyalkyl, carboxyaryl, trifluoromethyl, C1-C6 alkyl, C3-C7 cycloalkyl, C2-C10 heterocycle, C6-C12 aryl, C4-C10 heteroaryl, wherein in the group of Z41, Z42, Z43 and Z44, three or less within that group are N; wherein in the group of Z45, Z46, Z47 and Z48, three or less within that group are N; and wherein in the group of Z49, Z50, Z51 and Z52, three or less within that group are N; and
(X21) and (X22) indicate the site of bonding to X21 and X22 of formula (II), respectively;
K, when X22 is O or NR50, is selected from the group consisting of:
(X22)—(CH2)n26—(X23), (X22)—(CH2)n27a—X27—(CH2)n27b—(X23),
K, when X22 is N, is selected from the group consisting of:
where n26 is 2-10; n27a and n27b are independently 2-4; n28 is 0-4; n29 is 0-3; n30a, n30b and n30c are independently 0-4; n31a, n31b, n31c, n32a, n32b, n32c, n33a, n33b, n33c, n34a, n34b, n34c, n35a, n35b and n35c are independently 2-4, when X28a, X28b, X28c, X30a, X30b, X30c, X31a, X31b, X31c, X33a, X33b or X33c are CH2, n31a, n31b, n31c, n33a, n33b, n33c, n34a, n34b, n34c, n35a, n35b and n35c, respectively, can also be 0-1;
X27 is selected from the group consisting of O, CH═CH, S(O)q24 and NR55, where q24 is 0-2 and R55 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl or C4-C14 heteroaryl;
X28a, X28b, X28c, X30a, X30b, X30c, X31a, X31b, X31c, X33a, X33b and X33c are independently selected from the group consisting of CH2, O and NR56, where R56 is selected from the group consisting of hydrogen, C1-C4 alkyl, formyl, acyl and sulfonyl;
X29a, X29b and X29c are independently selected from the group consisting of O and NR57, where R57 is selected from the group consisting of hydrogen, C1-C4 alkyl, formyl, acyl and sulfonyl;
X32a, X32b and X32c are independently selected from the group consisting of O, S(O)q25, NR58 and CR59R60, where q25 is 0-2, R58 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-Cis aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl; R59 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C6 alkyl substituted with hydroxy, alkoxy, amino, mercapto, carboxy, carboxyalkyl, carboxyaryl, amido, amidino, guanidino, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl; and R60 is selected from the group consisting of hydrogen and C1-C6 alkyl; or R59 and R60 together with the carbon to which they are bonded form an optionally substituted three, four, five, six or seven-membered ring;
Z53, Z54, Z55, Z56, Z57, Z58, Z59, Z60, Z61, Z62, Z63, Z64, Z65, Z66, Z67, Z68, Z69, Z70, Z71, Z72, Z73, Z74, Z75 and Z76 are independently selected from the group consisting of N, N+—O− and CR61, where R61 is selected from the group consisting of hydrogen, hydroxy, alkoxy, amino, amido, amidino, guanidino, halogen, cyano, nitro, carboxy, carboxyalkyl, carboxyaryl, trifluoromethyl, C1-C6 alkyl, C3-C7 cycloalkyl, C2-C10 heterocycle, C6-C12 aryl, C4-C10 heteroaryl, wherein in the group of Z53, Z54, Z55 and Z56, three or less within that group are N; wherein in the group of Z57, Z58, Z59 and Z60, three or less within that group are N; wherein in the group of Z61, Z62, Z63 and Z64, three or less within that group are N; wherein in the group of Z65, Z66, Z67 and Z68, three or less within that group are N; wherein in the group of Z69, Z70, Z71 and Z72, three or less within that group are N; and wherein in the group of Z73, Z74, Z75 and Z76, three or less within that group are N; and
(X22) and (X23) indicate the site of bonding to X22 and X23 of formula (II), respectively;
R41, R42, R43, R44, R46 and R47 are independently selected from the group consisting of:
where (#) indicates the site of bonding of the moiety to the remainder of the structure; p11, p12, p13, p14 and p15 are independently 0-5; p16 and p17 are independently 0-6;
W11 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, amino acyl, amido, carboxyalkyl, carboxyaryl, amidino, sulfonyl, sulfonamido and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
W12 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, acyl, amino acyl and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
W13 and W18 are independently selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
W14 is selected from the group consisting of hydrogen, halogen, trifluoromethyl, hydroxy and methyl;
W15 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, formyl, acyl, carboxyalkyl, carboxyaryl, amido, amidino, sulfonyl, sulfonamido and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
W16 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, acyl, carboxyalkyl, carboxyaryl, amido and sulfonyl; and
W17 is selected from the group consisting of hydrogen, C1-C20 alkyl, C3-C15 cycloalkyl, C2-C14 heterocycle, C6-C15 aryl, C4-C14 heteroaryl, sulfonyl and C1-C8 alkyl substituted with C3-C15 cycloalkyl, C6-C15 aryl or C4-C14 heteroaryl;
wherein R41, when X23 is NR51, can also form an optionally substituted four, five, six or seven-membered ring together with NR51; and
wherein R42, when X21 is NR49, can also form an optionally substituted four, five, six or seven-membered ring together with NR49; and
R45a, R45b, R48a and R48b are independently selected from the group consisting of hydrogen, fluorine, C1-C10 alkyl, C6-C12 aryl, hydroxy, alkoxy, aryloxy and amino.

### Claim at position 21

60-66. (canceled)

### Claim 67 (depends on 59)

The library according to claim 59 comprising macrocyclic compounds selected from those with structures 3976-4121.

### Claim 68 (depends on 59)

The library according to claim 59 arrayed in at least one multiple sample holder.

### Claim at position 24

69-70. (canceled)

### Claim 71 (depends on 59)

A macrocyclic compound represented by formula (II) as described in claim 59, or salts thereof.

### Claim 72 (depends on 71)

The macrocyclic compound of claim 71 selected from the group consisting of structures 3976-4121 and pharmaceutically acceptable salts thereof.

### Claim at position 27

73-76. (canceled)

### Claim 77 (depends on 59)

A method of using the library according to claim 59, said method comprising contacting said compounds of said library with a biological target so as to obtain identification of compounds that modulate the biological target.

### Claim at position 29

78-81. (canceled)
